Vendor Intelligence Report: TSC Top Supplements China

Executive summary

TSC Top Supplements China is a product-specific vendor, not a vendor-wide yes/no call. Across 139 Finnrick lab tests, TSC records 99 pass / 39 fail for a 71% overall pass rate. The spread is sharp: GHK-Cu is the cleanest relative line, while Retatrutide sits in a better-supported but batch-sensitive middle. TB-500 and Tesamorelin carry the opposite signal, with fail-heavy performance and documented high-consequence outliers.

The lab story is not mild drift. The full record documents zero-identity failures, severe underfill, and weak batch traceability, including vials with no batch ID and inconsistent batch naming on the few that do appear. Ratings also contract under stricter grading, which matters for buyers treating a public purity score as fill assurance.

The OSINT side explains why recourse is thin. Registry, shipment, and personnel searches did not identify a verifiable legal entity, owner, address, or refund-policy layer; a plausible TSC domain archived as an unrelated fashion shop. The current public contact surface is a gated Discord invite, and a public forum record documents a multi-server suspension event that exposed the fragility of TSC’s ordering and testing channels.

This report is most useful if you are deciding whether TSC is viable for a specific peptide. It separates stronger lines from avoid-or-test-first lines, then ties those findings to channel stability, authentication risk, and the absence of a public accountability layer.

Inside the full report:

• Per-product Finnrick pass/fail rates, rating trajectories, and methodology-divergence charts for all 8 tested products
• Incident review covering zero-identity results, severe underfill, and underfill-plus-purity failure modes
• Registry, shipment, LinkedIn, and domain-history checks behind the no-entity/no-website finding
• GLP-1 Forum Discord suspension exhibit and analysis of TSC’s gated-channel operating model
• Operator-adjacent Reddit/private-community mapping and unresolved Telegram/payment-rail leads
• Batch traceability review, including absent batch IDs and inconsistent formats found in field records

Risk assessment

• Corporate opacity and buyer-recourse risk — high: Registry, domain, owner, address, refund-policy and merchant-identity checks found no public attribution layer; disputes depend on gated Discord access.
• High-risk product-quality failure risk: BPC-157, Tesamorelin and TB-500 — high: BPC-157 (45.01%) and Tesamorelin (46.14%) include zero-identity failures; TB-500 rates 25.51% with 0 passing tests in the supplied row.
• Semaglutide and Cagrilintide weak-line risk — medium: Semaglutide (57.37%) and Cagrilintide (59.34%) are weak, low-volume lines; require fresh batch-specific verification.
• Retatrutide and Tirzepatide batch-consistency risk — medium: Ratings are stronger (Retatrutide 80.93%; Tirzepatide 81.86%), but field notes include Retatrutide severe underfill and Tirzepatide zero-identity/underfill outliers.
• Traceability and recall risk — high: Many tested vials were described as no-label/no-batch-ID, and the few batch IDs use inconsistent formats.
• Platform-continuity and order-support disruption risk — high: Four TSC Discord servers were reportedly suspended in one November 2025 enforcement event, and no stable storefront was found.
• Brand-authentication and TSC-name confusion risk — medium: No official domain or channel list was found; unrelated domains and SEO spam can misdirect buyers searching the TSC name.
• Import seizure and legal-disruption risk — medium: No TSC-specific seizure surfaced, but China-to-US unapproved peptide shipments face documented CBP enforcement risk.